Norstella Launches Pipeline-to-Patient Productivity Index to Benchmark Biopharma Performance Across the Drug Development LifecycleUnusual Whales·1 day ago, 10:42 AM
CAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related DisorderUnusual Whales·2 days ago, 06:03 AMCAMP-4.39%
Aspire Biopharma Updates Public Warrant Exercise TermsTip Ranks·Jul 20 at 04:48 PMASBP-22.57%ASBPW-22.92%
ASPIRE BIOPHARMA HOLDINGS INC C/WTS 14/02/2030 (TO PUR COM) | 10-K: FY2025 Revenue: USD 6.202 KEarnings Watch·Apr 24 at 06:11 AMASBPW-22.92%
ASPIRE BIOPHARMA HOLDINGS INC C/WTS 14/02/2030 (TO PUR COM) | 10-Q: FY2025 Q3 Revenue: USD 1.941 KEarnings Watch·Nov 14, 2025 at 07:24 AMASBPW-22.92%
ASPIRE BIOPHARMA HOLDINGS INC C/WTS 14/02/2030 (TO PUR COM) | 10-Q: FY2025 Q2 EPS: USD -0.41Earnings Watch·Aug 13, 2025 at 04:04 PMASBPW-22.92%
ASPIRE BIOPHARMA HOLDINGS INC C/WTS 14/02/2030 (TO PUR COM) | 10-Q: FY2025 Q1 EPS: USD -0.42Earnings Watch·May 14, 2025 at 03:47 PMASBPW-22.92%
